| Literature DB >> 31885708 |
Changgong Lan1,2, Lizhen Long2, Kegong Xie2, Jia Liu2, Landao Zhou2, Shengcai Pan2, Junqing Liang2, Zhenyang Tu2, Ziran Gao2, Yujin Tang1,2.
Abstract
Role of microRNA-429 (miRNA-429) in osteogenic differentiation of hADMSCs was elucidated to explore the potential mechanism. Serum level of miRNA-429 in osteoporosis patients and controls was determined by quantitative real-time polymerase chain reaction (qRT-PCR). After H2O2 induction in hADMSCs, cell viability and reactive oxygen species (ROS) level were determined by cell-counting kit (CCK-8) assay and flow cytometry, respectively. Alkaline phosphatase (ALP) activity in H2O2-induced hADMSCs was also detected. The binding condition between miRNA-429 and SCD-1 was verified by dual-luciferase reporter gene assay. Relative levels of osteogenesis-related genes influenced by SCD-1 and miRNA-429 were detected by qRT-PCR. Furthermore, regulatory effects of SCD-1 and miRNA-429 on ALP activity and calcification ability of hADMSCs were evaluated. miRNA-429 was significantly upregulated in serum of osteoporosis patients. During the process of osteogenesis differentiation, H2O2 induction gradually upregulated miRNA-429 in hADMSCs. Overexpression of miRNA-429 markedly reduced ALP activity. Subsequent dual-luciferase reporter gene assay verified that miRNA-429 could bind to SCD-1 and negatively regulated its protein level in hADMSCs. SCD-1 was obviously downregulated in the osteogenesis differentiation of hADMSCs under oxidative stress. Moreover, silencing of SCD-1 suppressed expression of osteogenesis-related gene, ALP activity and calcification ability. Notably, SCD-1 knockdown partially reversed the regulatory effect of miRNA-429 on the osteogenic differentiation of hADMSCs. miRNA-429 suppresses the osteogenic differentiation of hADMSCs under oxidative stress via downregulating SCD-1. Copyright: © Lan et al.Entities:
Keywords: SCD-1; hADMSCs; miRNA-429; osteoporosis
Year: 2019 PMID: 31885708 PMCID: PMC6913378 DOI: 10.3892/etm.2019.8246
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Figure 1.miR-429 is upregulated in osteoporosis patients and activated under oxidative stress. (A) Relative level of miR-429 in serum samples of osteoporosis patients (n=30) and healthy controls (n=30) determined by qRT-PCR. (B) Cell viability in hADMSCs induced with 0, 50, 100 and 200 µM H2O2. (C) ROS level in hADMSCs induced with 0, 50, 100 and 200 µM H2O2. (D) Relative level of miR-429 in hADMSCs induced with 0, 50, 100 and 200 µM H2O2. (E) Relative level of miR-429 in hADMSCs with no treatment, NAC induction, 100 µM H2O2 induction and 100 µM H2O2 + NAC induction. *P<0.05.
Figure 2.Knockdown of miR-429 accelerated osteogenic differentiation of hADMSCs. (A) Relative level of miR-429 in hADMSCs cultured in osteogenic medium with or without 100 µM H2O2 induction for 0, 3, 7 and 14 days. (B) Relative ALP activity in hADMSCs cultured in osteogenic medium with or without 100 µM H2O2 induction for 0, 3, 7 and 14 days. (C) Relative level of miR-429 in hADMSCs cultured in osteogenic medium with 100 µM H2O2 induction and transfected with miR-429 mimics or inhibitor. (D) Relative ALP activity in hADMSCs cultured in osteogenic medium with 100 µM H2O2 induction and transfected with miR-429 mimics or inhibitor.*P<0.05.
Figure 3.SCD-1 is the target gene of miR-429. (A) Binding sequences between miR-429 and SCD-1 predicted by TargetScan. (B) Relative luciferase activity in hADMSCs co-transfected with miR-429 mimics/NC and wild-type/mutant-type SCD-1. (C) Relative level of SCD-1 in hADMSCs transfected with miR-429 mimics or inhibitor. (D) Protein level of SCD-1 in hADMSCs transfected with miR-429 mimics or inhibitor. *P<0.05.
Figure 4.miR-429 mediated osteogenic differentiation of hADMSCs via SCD-1. (A) Relative level of SCD-1 in hADMSCs cultured in osteogenic medium with or without 100 µM H2O2 induction for 0, 3, 7 and 14 days. hADMSCs cultured in osteogenic medium with100 µM H2O2 induction were transfected with scramble, SCD-1 siRNA, miR-429 inhibitor or SCD-1 siRNA+miR-429 inhibitor. (B) Relative levels of OC, RUNX2 and ALP; (C) ALP activity; (D) Calcification ability. *P<0.05.